Treatment for Chronic Lymphocytic Leukemia in Younger Patients

Study name: A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Description: Researchers at the WL Nugent Cancer Center are conducting a Phase III clinical trial to determine if a new combination of FDA-approved medications possibly reduces treatment time for patients with chronic lymphocytic leukemia.

  • Group 1 (investigational treatment):  Receive a combination of venetoclax, ibrutinib, & obinutuzumab for treatment.
  • Group 2 (current standard treatment): Receive ibrutinib & obinutuzumab for treatment.

Who can participate?

This study is open to men and women between the ages of 18 and 69 who have been diagnosed with chronic lymphocytic leukemia and have not yet received treatment for the disease.

What to expect

  • You will meet with your doctor to discuss what is involved in the study and the possible benefits and risks. If you and your doctor agree this clinical trial is right for you, you will be asked to sign a consent form.

  • This is a randomized study, where you will be assigned by chance to one of the treatment groups listed above.

  • You will periodically complete questionnaires about your condition, side-effects from treatment, etc.

  • Blood samples may be collected before, during, and after treatment for study analysis.


Please talk with your doctor about whether this clinical trial is right for you.